Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Hypermetropia, Spastic gait, Optic nerve dysplasia, and Nystagmus and others; and common findings: Astigmatism, Strabismus, Delayed CNS myelination, and Dilated third ventricle and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Spastic gait, Intellectual disability, Overactive reflexes (hyperreflexia) |
KIDINS220 encodes kinase D interacting substrate 220 (1,771 aa). Promotes a prolonged MAP-kinase signaling by neurotrophins through activation of a Rap1-dependent mechanism. Highest expression in Brain Cerebellar Hemisphere (55.4 TPM) and Brain Cerebellum (40.8 TPM).
Spastic paraplegia, intellectual disability, nystagmus, and obesity has been associated with mutations in the KIDINS220 gene on chromosome 2.
The KIDINS220 protein participates in Prolonged ERK activation events pathway.
KIDINS220 is classified as a druggable target (Kinase category) with score 0.0.
Genetic testing for KIDINS220 is available. Testing is considered supportive for diagnosis.
Phenotype severity distribution: 15 always present features, 18 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for spastic paraplegia, intellectual disability, nystagmus, and obesity.
7 publications have been identified in PubMed for spastic paraplegia, intellectual disability, nystagmus, and obesity. Research spans Case Report / Case Series (43%), Basic Science / Preclinical (29%), and Review / Meta-Analysis (14%).
Fernández-Albarral JA (2025). [PMID: 39939990](https://pubmed.ncbi.nlm.nih.gov/39939990/). *Fluids Barriers CNS*. [Basic Science / Preclinical]
Qi H (2024). [PMID: 39129698](https://pubmed.ncbi.nlm.nih.gov/39129698/). *Actas Esp Psiquiatr*. [Case Report / Case Series]
Miremberg H (2024). [PMID: 39367534](https://pubmed.ncbi.nlm.nih.gov/39367534/). *Prenat Diagn*. [Case Report / Case Series]
Bonati MT (2024). [PMID: 39336781](https://pubmed.ncbi.nlm.nih.gov/39336781/). *Genes (Basel)*. [Review / Meta-Analysis]
Alstrup M (2024). [PMID: 39033379](https://pubmed.ncbi.nlm.nih.gov/39033379/). *Genet Med*. [Epidemiology / Natural History]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 9:33 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Eyes |
3 |
Strabismus, Optic nerve dysplasia, Nystagmus |
Arms and legs | 3 | Lower limb hypertonia, Limb hypertonia, Tip-toe gait |
Muscles | 2 | Axial hypotonia, Brain shrinkage (cerebral atrophy) |
Age of onset: before birth.
Yang W (2024). [PMID: 39296002](https://pubmed.ncbi.nlm.nih.gov/39296002/). *Heliyon*. [Basic Science / Preclinical]
Al Hussein HS (2024). [PMID: 39109120](https://pubmed.ncbi.nlm.nih.gov/39109120/). *Cureus*. [Case Report / Case Series]